申聯生物(688098.SH):世之源三個創新藥管線尚處於不同的研發階段
格隆匯8月18日丨申聯生物(688098.SH)公佈股票交易異常波動公告,公司關注到近期市場對創新藥業務關注度較高。公司於2025年2月6日披露《關於全資子公司對外投資暨關聯交易的公告》,公司通過全資子公司上海本天成生物醫藥有限公司向世之源增資6,000萬元並取得世之源20.48%的股份,公司開始佈局人用創新藥領域。世之源擁有艾滋病治療單克隆抗體藥物(UB-421)、抗過敏Anti-IgE單克隆抗體藥物(UB-221)以及抗單純皰疹病毒單克隆抗體藥物(UB-621)等管線在中國大陸的臨牀及商業化權利。公司於2025年8月11日披露《申聯生物醫藥(上海)股份有限公司投資者關係活動記錄表(20250806-20250808)》,公司發佈信息後,部分媒體也發佈了相關報道。
截至本公告披露日,世之源三個創新藥管線尚處於不同的研發階段。其中,UB-221已由世之源在中國大陸全面開啓臨牀II期試驗;UB-421與UB-621將由世之源依據其戰略及全球臨牀數據,靈活調整國內臨牀策略與實施進度。上述創新藥管線的臨牀試驗能否成功還存在重大不確定性。除前述信息外,公司目前未發現其他對公司股票交易價格可能產生重大影響的媒體報告或市場傳聞,不涉及其他市場熱點概念事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.